News & Events about Amylyx Pharmaceuticals Inc.
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (Amylyx or the Company) will report its first quarter 2023 financial results on Thursday, May 11, 2023, following the close of the U.S. financial markets. Amylyx senior management team will host a conference call and audio webcast at 4:30 p.m. ET to...
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (Amylyx or the Company) today announced that the first participant has been dosed in the HELIOS study, a Phase 2 clinical trial of AMX0035 (sodium phenylbutyrate [PB] and taurursodiol [TURSO]) for the treatment of Wolfram syndrome (WS). HELIOS is an...
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (Amylyx or the Company) today announced that Joshua Cohen and Justin Klee, Co-CEOs of Amylyx, will participate in the 22nd Annual Needham Virtual Healthcare Conference. The conference is being conducted in a virtual format, and the presentation will take...
InvestorPlace
2 months ago
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
If you can handle the risks associated with high volatility, these biotech stocks to buy might double the returns in your portfolio.
The post 7 Biotech Stocks to Buy for 100% Returns appeared first on InvestorPlace...
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX Get Rating) was the target of a large growth in short interest in March. As of March 15th, there was short interest totalling 5,860,000 shares, a growth of 7.3% from the February 28th total of 5,460,000 shares. Approximately 13.8% of the shares of the ...